Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as bivalent enterovirus vaccine (Vero cell), inactivated, bivalent enterovirus vaccine, inactivated
low dose Bivalent Enterovirus Vaccine, Inactivated · 2 trials · 3 indications
Evaluate the primary vaccine efficacy of the trial vaccine against HFMD caused by CA16 infection, diagnosed by RT-PCR, in children aged 6 to 71 months (with and without a history of EV71 vaccination) 14 days after full vaccination (based on data from at least 47 cases). The vaccine's efficacy will be evaluated by monitoring the annual incidence rate of HFMD attributable to CA16 infection, as confirmed by reverse transcription polymerase chain reaction (RT-PCR) nucleic acid testing, following complete full immunization for 14 days based on data from at least 47 cases until the end of one epidemic seasons.
Evaluate the seroconversion rate and geometric mean titer (GMT) of EV71 neutralizing antibodies in participants aged 6-71 months without a history of EV71 vaccination and negative for EV71 antibodies before immunization, 30 days after full vaccination.
the incidence rates of adverse reactions from the start of vaccination to 30 days after the end of the entire vaccination course
The seroconversion rate of EV71 and CA16 neutralizing antibodies in children aged 6-71 months 30 days after the end of the entire vaccination course.
| Arm | Type | Description |
|---|---|---|
| trial group | EXPERIMENTAL | Bivalent enterovirus inactivated vaccine (Vero cell) |
| control group | ACTIVE_COMPARATOR | Enterovirus Type 71 Vaccine (Vero Cell), Inactivated |
| low-dose experimental group | EXPERIMENTAL | phase Ⅰ: 18\~59 years old,6\~12 years old,6\~71 months old; phase Ⅱ：6\~71 months old |
| medium-dose experimental group | EXPERIMENTAL | phase Ⅰ: 18\~59 years old,6\~12 years old,6\~71 months old; phase Ⅱ：6\~71 months old |
| high-dose experimental group | EXPERIMENTAL | phase Ⅰ: 18\~59 years old,6\~12 years old,6\~71 months old; phase Ⅱ：6\~71 months old |
| Active control group | ACTIVE_COMPARATOR | phase Ⅰ: 6\~71 months old; phase Ⅱ：6\~71 months old |
| Name | Type | Description |
|---|---|---|
| bivalent enterovirus vaccine (Vero cell), inactivated | BIOLOGICAL | Two doses are administered with a one-month interval between each dose. |
| Enterovirus Type 71 Vaccine (Vero Cell), Inactivated | BIOLOGICAL | Two doses are administered with a one-month interval between each dose. |
| low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | BIOLOGICAL | Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml |
| medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | BIOLOGICAL | Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml |
| high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | BIOLOGICAL | Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml |
| Enterovirus type EV71 vaccine (Vero cell), Inactivated | BIOLOGICAL | Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac) |
Inclusion Criteria: * Healthy children aged 6 to 71 months with no history of EV71 vaccination; or healthy children aged 24 to 71 months who have completed two doses of EV71 vaccine at least 6 months prior. * Guardians who can understand and voluntarily sign the informed consent form. * Willing and...
The low dose Bivalent Enterovirus Vaccine, Inactivated is an investigational vaccine developed by Sinovac Biotech, Ltd for the prevention of Hand, Foot and Mouth Disease (HFMD). It is a bivalent, inactivated vaccine produced using Vero cell technology, designed to protect against enterovirus infections that cause HFMD.
It is being developed for the prevention of Hand, Foot and Mouth Disease (HFMD), a common infectious disease in young children. Clinical trials have also enrolled participants with herpangina as a related condition. The vaccine is intended for healthy volunteers, with trial enrollment starting at 6 months of age.
Sinovac Biotech, Ltd is developing the low dose Bivalent Enterovirus Vaccine, Inactivated. Sinovac Biotech trades under the ticker SVA. The company is the sponsor of the clinical trials evaluating this vaccine candidate.
The low dose Bivalent Enterovirus Vaccine, Inactivated is in clinical development. A Phase 1/2 trial (NCT06063057) has been completed, and a Phase 3 trial (NCT06734832) is currently recruiting. The vaccine is investigational and has not been approved for commercial use.
Two trials have evaluated this vaccine. NCT06063057 was a completed Phase 1/2 trial with 744 participants in China. NCT06734832 is a recruiting Phase 3 trial with an planned enrollment of 8,000 participants in China. Both trials enrolled healthy volunteers starting at 6 months of age.
Yes. The low dose Bivalent Enterovirus Vaccine, Inactivated is also known as bivalent enterovirus vaccine (Vero cell), inactivated, and bivalent enterovirus vaccine, inactivated. These names refer to the same Sinovac Biotech vaccine candidate for Hand, Foot and Mouth Disease.